Annual reassessments are prepared by pharmaceutical companies to conduct an annual evaluation of the product performance. They usually report the overall product’s status (including efficacy, safety, and market performance developments), which ensures the product remains compliant with regulatory standards. These documents require the tracking of a wide range of data from different sources. For this reason, we strive to provide a cohesive and synthesise document, ensuring that all key aspects are thoroughly evaluated and communicated.